GlassScriptPhysician profile
Paul D Garrett
NPI 1639160823
$24,289.91
in general payments reported to CMS, 2019-2025
40 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,150 · 2021: $3,010 · 2022: $5,081 · 2023: $1,334 · 2024: $1,374 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,100.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $14,387.95 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,739.61 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,319.36 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,071.99 | 2019-2025 | Lifevest |
| Amgen INC. | $682.27 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $597.83 | 2019-2025 | |
| Esperion Therapeutics, INC. | $545.53 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $395.32 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $389.25 | 2019-2024 | Farxiga, Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $384.43 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $350.09 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Kestra Medical Technology Services, INC. | $347.94 | 2022-2025 | Assure Wcd |
| Medtronic Vascular, INC. | $264.16 | 2019-2020 | |
| Abiomed | $253.18 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.68 | 2019-2024 | Jardiance |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $138.18 | 2019-2020 | |
| Heartflow, INC. | $126.71 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $119.00 | 2019-2024 | |
| Chiesi USA, INC. | $87.28 | 2020-2022 | |
| Novo Nordisk INC | $79.78 | 2020-2025 | Wegovy, Ozempic |
| Akcea Therapeutics, INC. | $77.21 | 2019-2020 | |
| Amarin Pharma, INC. | $76.30 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $76.30 | 2024-2025 | Uptravi |
| Cleerly, INC. | $58.50 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals International, Plc | $53.13 | 2024 | Arcalyst |
| Medtronic, INC. | $48.66 | 2023-2024 | Linq II |
| Inspire Medical Systems, INC. | $44.98 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $44.85 | 2019 | |
| Irhythm Technologies, INC. | $44.71 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Philips North America LLC | $40.63 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Otsuka America Pharmaceutical, INC. | $39.66 | 2019 | |
| Scpharmaceuticals INC. | $37.27 | 2024-2025 | |
| Lundbeck LLC | $31.35 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $29.04 | 2022-2023 | Arcalyst |
| Itamar Medical INC | $23.58 | 2023 | Watchpatone |
| United Therapeutics Corporation | $21.23 | 2025 | Tyvaso |
| Alnylam Pharmaceuticals INC. | $18.20 | 2020 | |
| Baxter Healthcare | $16.95 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2019 | |
| Genzyme Corporation | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.